DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category CRMD
CorMedix Inc
CorMedix Therapeutics (Nasdaq: $CRMD): Rezzayo Delivers, the Platform Thesis Gets Stronger
Today’s ReSPECT readout removes one major clinical uncertainty from the CorMedix story. The next layer is execution: pre-NDA interaction with FDA, a targeted sNDA in the second half of 2026, DefenCath pricing after July 1, 2026, possible 2027 add-on improvement, and any favorable evolution in the policy/legal framework around TDAPA and dialysis-drug access.
CorMedix ($CRMD): the real second chapter after commercialization
DefenCath is no longer just a launch story, and CorMedix is no longer easy to reduce to a one-drug binary. The company now has real revenue, positive adjusted EBITDA, a broader anti-infective platform after the Melinta transaction, and an approaching Phase 3 readout for REZZAYO. But it also has one very specific pressure point that still dominates the equity story: the July 1, 2026 reimbursement transition for DefenCath. This report is built to cover every major angle ahead of the ReSPECT topline update and to explain, from first principles, why the reimbursement framework matters so much.
CorMedix (CRMD) – From single-asset grind to commercial anti-infective platform
A narrative and technical deep dive on CorMedix after full-year 2025 and Q4 numbers: what DefenCath plus Melinta really changed, how the new P&L looks, and where the risk-reward sits going into 2026–2027.
CRMD Thinking After Hours
This after-hours note starts from a simple, honest message in the comments. A reader who first bought CRMD around 11 USD, then averaged down at 9 USD and again at 6.5 USD, with one clear idea: one day, selling “north of 15” if the CorMedix story plays out.
CRMD CorMedix Inc
CorMedix is no longer the pre-revenue story that dialysis investors watched from a distance. After the U.S. launch of DefenCath in 2024, the company has delivered its first profitable quarter, acquired the Melinta anti-infective portfolio, built a meaningful cash position and, as of February 2026, added a $75 million share repurchase program on top.
CRMD Cormedix Inc jan 12 Legislative update (KCAPA 2026)
CorMedix Inc. has crossed a line that many small biotechs never reach. It is no longer a binary, pre-revenue story waiting for a single FDA decision. With DefenCath approved, the Melinta acquisition closed and several hundred million dollars of revenue on the board, CRMD now behaves like a small-cap specialty pharma focused on preventing and treating serious infections linked to vascular access.